NCT00598325View on ClinicalTrials.gov

Antibody and Safety Study of 6 Doses of NicVAX in Smokers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Smoking
Interventions
BIOLOGICAL

3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)

1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)

Trial Locations (1)

20850

Accelovance, Inc., Rockville

Sponsors
All Listed Sponsors
lead

Nabi Biopharmaceuticals

INDUSTRY

NCT00598325 - Antibody and Safety Study of 6 Doses of NicVAX in Smokers | Biotech Hunter | Biotech Hunter